ChiCTR2100049972 版本V1.1 版本创建时间2022/03/26 15:36:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100049972 

最近更新日期:

Date of Last Refreshed on:

2022-03-15 20:24:37 

注册时间:

Date of Registration:

2021-08-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

生命早期营养、肠道微生态和骨骼成熟与健康的关系

Public title:

Nutrition, microbiome and bone maturation during early life related to health

注册题目简写:

English Acronym:

研究课题的正式科学名称:

生命早期营养、肠道微生态和骨骼成熟与健康的关系

Scientific title:

Nutrition, microbiome and bone maturation during early life related to health

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王晶 

研究负责人:

刘功姝 

Applicant:

Wang Jing 

Study leader:

Liu Gongshu 

申请注册联系人电话:

Applicant telephone:

+86 15620138816

研究负责人电话:

Study leader's
telephone:

+86 13920316213

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangjing8162012@163.com

研究负责人电子邮件:

Study leader's E-mail:

liugongshu727@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市和平区贵州路96号

研究负责人通讯地址:

天津市和平区贵州路96号

Applicant address:

96 Guizhou Road, Heping District, Tianjin

Study leader's address:

96 Guizhou Road, Heping District, Tianjin

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津市妇女儿童保健中心

Applicant's institution:

Tianjin Women's and Children's Health Center

研究负责人所在单位:

天津市妇女儿童保健中心

Affiliation of the Leader:

Tianjin Women's and Children's Health Center

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

HZ20210521

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津市妇女儿童保健中心医学伦理委员会

Name of the ethic committee:

Ethics Committee of Tianjin Women's and Children's Health Center

伦理委员会批准日期:

Date of approved by ethic committee:

2021-05-20 00:00:00

伦理委员会联系人:

张钰

Contact Name of the ethic committee:

Zhang Yu

伦理委员会联系地址:

天津市和平区贵州路96号

Contact Address of the ethic committee:

96 Guizhou Road, Heping District, Tianjin

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津市妇女儿童保健中心

Primary sponsor:

Tianjin Women's and Children's Health Center

研究实施负责(组长)单位地址:

天津市和平区贵州路96号

Primary sponsor's address:

96 Guizhou Road, Heping District, Tianjin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市妇女儿童保健中心

具体地址:

和平区贵州路96号

Institution
hospital:

Tianjin Women's and Children's Health Center

Address:

96 Guizhou Road, Heping District

经费或物资来源:

雀巢(瑞士)公司提供

Source(s) of funding:

Supported by Société des Produits Nestlé S.A.

研究疾病:

肠道微生态和骨健康  

Target disease:

microbiome and bone maturation

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1. 定义在健康婴儿(正常生长发育、无感染、过敏、抗生素需求)中的适龄肠道微生态的成熟过程; 2. 确定饮食因素(包括母乳喂养、断奶时引入固体食物、3岁前总体营养和饮食模式)如何影响适龄群肠道微生态轨迹; 3. 定义从 0 到 1 岁的胫骨轨迹,以确定曲线的形状、曲率点和该曲率点前后的斜率; 4. 评估生命早期营养(母乳喂养和配方奶喂养)喂养方案如何影响前一个目的定义的 0 至 1 岁胫骨轨迹; 5. 评估饮食因素如何通过肠道微生态影响婴儿健康。  

Objectives of Study:

1. Define the maturation process of the age-appropriate gut microbiome in healthy infants (normal growth and development, no infections, allergies, antibiotic needs); 2. Determine how dietary factors (including breastfeeding, introduction of solid foods at weaning, overall nutrition and dietary patterns before age 3 years) affect the gut microbiome trajectories in age-appropriate groups; 3. Define the tibial trajectory from 0 to 1 year old to determine the shape of the curve, the point of curvature and the slope before and after that point of curvature; 4. To assess how early life nutrition (breastfeeding and formula feeding) feeding regimens affect the 0 to 1 year tibial trajectory defined by the previous purpose; 5. Assess how dietary factors affect infant health through the gut microbiome.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 已获得其父母(或其法定代理人 [LAR])的书面知情同意,并有亲自签署并注明日期的知情同意书的证据表明,已向受试者的父母/LAR 告知了研究的所有相关方面;
2. 受试者的父母/LAR 达到法定同意年龄,愿意并能够满足研究方案的要求;
3. 对于第 1 组,为出生(出生日期 = 第 0 天)后 ≤ 10 天的健康婴儿。对于第 2 组,为最大年龄为 6 月龄的健康婴儿;
4. 足月妊娠分娩(≥ 37 周且 ≤ 42 周);
5. 在整个研究过程中,可通过电话直接联系到受试者的父母/LAR;
6. 登记的父母双方在其管辖范围内都有固定的工作和/或住所。

Inclusion criteria

1. Written informed consent has been obtained from their parents (or their legal representative [LAR]) and evidence of a personally signed and dated informed consent form indicates that the subject's parents/LAR have been informed of the study all relevant aspects;
2. The subject's parents/LARs have reached the legal age of consent and are willing and able to meet the requirements of the research protocol;
3. For group 1, healthy infants <= 10 days after birth (date of birth = day 0). For group 2, healthy infants up to 6 months of age;
4. Full-term pregnancy and delivery (>= 37 weeks and <= 42 weeks);
5. The subject's parents/LARs can be directly contacted by telephone throughout the study;
6. Both registered parents have regular employment and/or residence within their jurisdiction.

排除标准:

1. 通过医疗访谈/病历(如可用)评估发现的妊娠合并症(如先兆子痫、妊娠期糖尿病、肠病);
2. 目前正在参与或在试验开始前 4 周内曾经参与另一项临床试验。

Exclusion criteria:

1. Pregnancy comorbidities (eg, preeclampsia, gestational diabetes mellitus, enteropathy) assessed through medical interviews/medical records (if available);
2. Are currently participating in or have participated in another clinical trial within 4 weeks prior to the start of the trial.

研究实施时间:

Study execute time:

From 2021-10-01 00:00:00 To 2025-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-10-01 00:00:00 To 2022-12-31 00:00:00

干预措施:

Interventions:

组别:

1组

样本量:

690

Group:

group 1

Sample size:

干预措施:

观察

干预措施代码:

Intervention:

Observe

Intervention code:

组别:

2组

样本量:

690

Group:

group 2

Sample size:

干预措施:

观察

干预措施代码:

Intervention:

Observe

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津市 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市妇女儿童保健中心 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Women's and Children's Health Center

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

身高/身长

指标类型:

主要指标

Outcome:

height/length

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

主要指标

Outcome:

weight

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

骨强度

指标类型:

主要指标

Outcome:

bone mass index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

桡骨长度

指标类型:

主要指标

Outcome:

radius bone length

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胫骨长度

指标类型:

主要指标

Outcome:

tibia bone length

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

stool

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

母乳

组织:

Sample Name:

breast milk

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 1 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not Applicable

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

private

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集使用病例记录表(Case Record Form, CRF)收集.

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection uses case record form.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-08-15 05:04:46